Natera (NTRA) Stock Forecast & Price Target

Natera Inc. is expected to experience significant revenue growth driven by its Signatera molecular residual disease (MRD) testing, with a notable quarterly increase of 21,500 tests translating to 54% year-over-year growth. The company anticipates expanding reimbursement coverage across various cancer types, which is likely to enhance average selling prices (ASP), gross margins (GMs), and operating cash flow. Additionally, Natera's recent quarterly performance reflected a strong revenue beat of approximately $80 million, accompanied by an upward revision of its 2025 revenue guidance by $160 million.

Natera Inc is facing a negative outlook primarily due to anticipated margin erosion driven by reduced in-network pricing as more commercial payors are expected to enter the market, impacting the average selling price (ASP) of its Panorama test. The company is also vulnerable to potential regulatory issues, delays in product launches, or shortfalls in financial performance, all of which could negatively influence its stock performance significantly. Furthermore, Natera’s expansion efforts may be hindered by a lack of compelling data and challenges related to pricing and reimbursement in emerging markets, further complicating its growth trajectory.